A grant from the Engineering and Physical Sciences Research Council (EPSRC) will support research into antibody-drug conjugate (ADC) linker technology
This 3-year grant is , part of a recently announced £80 million investment in cutting-edge multidisciplinary research.
The project will complement the translational research at Siftr Bio, a new spinout from Imperial College London, through ongoing close collaboration in the field of precision drug delivery. Our innovative technology platform uses patient tumour samples to rapidly identify novel ADC linkers, paving the way for more targeted and effective cancer therapeutics.
This ambitious research project will be driven by a highly multidisciplinary team, including clinicians, two skilled technicians, and three postdoctoral researchers (PDRAs) with expertise spanning high-throughput synthesis, chemical biology, and proteomics. Together, they will develop diverse workflows to explore and optimise linker chemistry for therapeutic applications.
Supporters
Article text (excluding photos or graphics) © Imperial College London.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.
Reporter
Edward Bartlett
Department of Chemistry
